Prenatal lymphoma treatment appears safe for both mothers and infants

11/12/2013 | DailyRx.com

Administration of standard non-antimetabolite chemotherapies for both Hodgkin lymphoma and non-Hodgkin lymphoma in the second and third trimester of pregnancy led to minimum incidence of maternal and fetal negative outcomes, a study from Tufts Medical Center found. At 41 months, progression-free survival and overall survival were 85% and 97%, respectively, in women with Hodgkin lymphoma, researchers reported in the Journal of Clinical Oncology.

View Full Article in:

DailyRx.com

Published in Briefs:

SmartBrief Job Listings for Health Care